Harrow (HROW) Expected to Announce Earnings on Monday

Key Points

• Harrow (HROW) is set to report its Q2 2025 earnings on August 6th, with analysts anticipating an earnings per share (EPS) of $0.01 and revenues of $64.23 million.
• In its previous earnings report, Harrow missed expectations with a reported loss of $0.38 EPS and $47.83 million in revenue, falling short of the $57 million estimate.
• Despite recent struggles, Harrow has an average analyst rating of "Buy" with a consensus price target of $63.83, indicating positive sentiment among analysts.

Harrow (NASDAQ:HROW - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results after the market closes on Monday, August 11th. Analysts expect Harrow to post earnings of $0.01 per share and revenue of $64.23 million for the quarter. Harrow has set its FY 2025 guidance at EPS.

Harrow (NASDAQ:HROW - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.40). The firm had revenue of $47.83 million for the quarter, compared to analysts' expectations of $57.00 million. Harrow had a negative return on equity of 25.01% and a negative net margin of 10.19%. On average, analysts expect Harrow to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Harrow Trading Down 1.7%

NASDAQ HROW traded down $0.53 on Friday, hitting $31.23. 530,570 shares of the stock were exchanged, compared to its average volume of 442,110. The company has a debt-to-equity ratio of 2.01, a quick ratio of 0.85 and a current ratio of 0.91. The stock has a fifty day moving average price of $31.76 and a two-hundred day moving average price of $28.78. The firm has a market capitalization of $1.15 billion, a P/E ratio of -55.77 and a beta of 0.41. Harrow has a 52-week low of $20.85 and a 52-week high of $59.23.

Wall Street Analyst Weigh In

HROW has been the subject of several recent analyst reports. BTIG Research initiated coverage on shares of Harrow in a research note on Thursday, June 12th. They set a "buy" rating and a $62.00 price objective for the company. HC Wainwright boosted their target price on shares of Harrow from $57.00 to $60.00 and gave the stock a "buy" rating in a report on Monday, May 12th. Cantor Fitzgerald initiated coverage on shares of Harrow in a research note on Friday, July 11th. They issued an "overweight" rating and a $76.00 target price for the company. Finally, William Blair assumed coverage on Harrow in a research report on Tuesday, June 10th. They issued an "outperform" rating on the stock. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $63.83.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HROW. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Harrow by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,146 shares of the company's stock worth $483,000 after acquiring an additional 790 shares during the last quarter. Royal Bank of Canada boosted its holdings in Harrow by 102.5% during the 1st quarter. Royal Bank of Canada now owns 9,813 shares of the company's stock valued at $261,000 after acquiring an additional 4,967 shares during the period. Finally, Strs Ohio purchased a new position in shares of Harrow in the 1st quarter valued at about $149,000. Hedge funds and other institutional investors own 72.76% of the company's stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.